Fig. 3
TRIM25 knockdown inhibits GBM cell growth in vivo. A In vivo experimental workflow: a 5 × 105 transfected glioma cells were harvested from cell culture dishes and implanted into the frontal lobes of nude mice. b In vivo bioluminescence imaging of the xenograft models was performed on days 5/7, 10/14, and 20/28 after cell implantation (the numbers of mice subjected to in vivo bioluminescence imaging were as follows: LN229, 6 for sh-NC-Luc and 5 for sh-TRIM25-2-Luc; U251, 5 for sh-NC-Luc and 5 for sh-TRIM25-1-Luc; and GBM#021, 6 for sh-NC-Luc and 6 for sh-TRIM25-2-Luc). c Animals were humanely euthanized by cervical dislocation when they showed signs of continuous discomfort, such as severe hunchback posture, decreased activity, apathy, leg dragging, or > 20% weight loss. B, C Images and quantification of in vivo bioluminescence in transfected LN229 and U251 cell-derived xenografts at indicated times. D Kaplan–Meier survival analysis performed with survival data from indicated groups. E Images and quantification of in vivo bioluminescence in transfected GBM#021 cell-derived xenografts at indicated times. F Kaplan–Meier survival analysis performed with survival data from indicated groups. ns: not significant, ∗: p < 0.05, ∗∗: p < 0.01, ∗∗∗: p < 0.001, and ∗∗∗∗: p < 0.0001